Controversies in Neuro-Oncology

Avastin and Malignant Gliomas

Indexed in: Chemical Abstracts, EBSCO, Ulrich's Periodicals Directory.

Neuro-oncology is an embryonic field of cancer research with a number of clinical trials in progress. However, the prognosis on neuro-oncologic patients has remained poor. Moreover, several small ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



Development of Sorafenib in Malignant Gliomas: Rationale and Early Clinical Experience

Pp. 162-170 (9)

Rachel Grossman and Jaishri Blakeley

Abstract

Sorafenib is a multi-targeted receptor tyrosine kinase inhibitor (TKI), with activity against vascular endothelial growth factor receptor-1 (VEGFR-1), VEGFR-2, VEGFR-3, Raf-1, B-Raf, C-Raf, and plateletderived growth factor receptor (PDGFR) -α and -β. Currently, sorafenib has regulatory approval for use in metastatic renal cell carcinoma and hepatocellular carcinoma. An attractive activity profile, pre-clinical evidence of antitumor activity in human malignant glioma models and a promising safety profile have led to recent phase I/II clinical trials for patients with malignant gliomas. Here we review the current data, and future directions for the development of sorafenib for malignant glioma.

Affiliation:

Department of Neurosurgery and Neurology and Johns Hopkins School of Medicine, Baltimore, MD.